Ly­me vac­cine test com­ple­tion is pushed back by a year as Pfiz­er, Val­ne­va say they'll ad­just tri­al

Val­ne­va and Pfiz­er have ad­just­ed the end date for the Phase III study of their in­ves­ti­ga­tion­al Ly­me dis­ease vac­cine, push­ing it back by a year af­ter is­sues at a con­tract re­searcher led to thou­sands of US pa­tients be­ing dropped from the test.

In a March 20 up­date to clin­i­cal­tri­als.gov, Val­ne­va and Pfiz­er moved the pri­ma­ry com­ple­tion date on the tri­al, called VAL­OR, from the end of 2024 to the end of 2025.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN